28 October 2015
New KitoZyme clinical study completed with promising results
A new clinical study involving around 100 persons has demonstrated excellent results achieved with KiOnutrime-CsG, which helps combat excess weight and obesity
KitoZyme operates in three segments of the healthcare sector: digestive health, weight management and cardiovascular health. The study related to a product within weight management has just been completed. More specifically, the objective was to verify and demonstrate the reduction in bodyweight in overweight and obese subjects as a result of the lipid-absorbing capacity of KiOnutrime, an innovative product developed by KitoZyme and derived from natural fibre of fungal origin.
The conclusion and results of this clinical study are very promising since patients recorded a clear, progressive reduction in their weight. Around 100 patients were involved in the study which also demonstrated statistically significant reductions in body fats and abdominal, hip and waist measurements in people who took KiOnutrime-CSG. The full results of the study are soon to be published in a renowned scientific journal.
The clinical trial requirements in detail
The multicentre clinical trial took place in four hospitals and medical research centres between the end of 2014 and the start of 2015. A total of 96 people - men and women who were overweight (BMI of 26-35) and aged between 18 and 65 years - were divided into two groups. The 64 people in the treatment group were given five capsules per day, each containing 500 mg of KiOnutrime-CsG. The 32 people enrolled in the control group followed the same procedure but their capsules contained a placebo. All patients maintained their usual eating habits and did not change their lifestyle. Weight loss was on average 3.2 kg in the group receiving treatment.
The unique nature of KitoZyme’s chitosan
KiOnutrime-CsG is a unique natural fibre extracted from fungi using a patented process developed by KitoZyme. It dissolves in 10 minutes in the acidic environment of the stomach. That means that a dose can be administered almost immediately before a meal which makes it convenient and easy for consumers to take. It is also suitable for vegetarians and is certified halal and kosher.
KiOnutrime-CsG is authorised in the EU under the Novel Food Regulation and is also approved by EFSA to bear the health claim that it maintains a healthy level of cholesterol (lipid) in the blood. The active ingredient also holds GRAS status as awarded by the US FDA.